Pibrentasvir
Pibrentasvir. Pan-genotypic HCV NS5A inhibitor — blocks viral RNA replication and assembly. Co-formulated with glecaprevir as Mavyret. >97%… Oral half-life 25 h.
Pan-genotypic HCV NS5A inhibitor — blocks viral RNA replication and assembly. Co-formulated with glecaprevir as Mavyret. >97% sustained viral response across HCV genotypes 1–6 in 8-week treatment-naive regimens.
PK: THE DEFECT WAS FOUND FROM ITS PARTNER RECORD, AND CONFIRMED HERE. Its citation was fetched in full and states no absorption rate, no volume, no bioavailability and no half-life — only ratios, which is the etravirine shape exactly. That reference is KEPT, because it is the legitimate interactions citation for the glecaprevir-pibrentasvir pair. THREE MUTUALLY INCONSISTENT HALF-LIVES EXIST AND THE STORED 23 WAS NONE OF THEM: the label says 13, the monotherapy first-in-human study says "ranged from 20 to 22 hours" (a range, so storing 21 would be a defect of its own), and the co-formulated value is the verbatim "a terminal elimination half-life of 5.9 and 25 hours". The stored values describe the COMBINATION state and nothing in the record said so. F 0.10 is unsourced AND unsourceable — the Mavyret label states no bioavailability and no volume for either component and there is no human intravenous pibrentasvir — so it is pinned to 1 and the volume carries the same apparent quantity it always did. TWO OF MY PRIORS ABOUT THIS PAIR WERE REFUTED AND ARE RECORDED: the boosting is ONE-DIRECTIONAL, and "Food had minimal effect (<14%) on pibrentasvir bioavailability" ALONE while the coformulated tablet does show one — the two must not be collapsed.
Pharmacokinetics
- Oral — t½ 25 h · F 100% · ka 0.66 h⁻¹ · Vd 2350 L
Sources: PMID:28688001, PMID:28464496, PMID:37661787